Table 2.
Phytocannabinoids and synthetic cannabinoids/cannabinoid signaling compounds covered in this review
| Cannabinoid | Abbreviation | Type | Target | Reference |
|---|---|---|---|---|
| Δ9-Tetrahydro-cannabinol | THC | phyto | CB1/CB2, direct antioxidant | Howlett et al., 1984; Hampson et al., 1998; Baker et al., 2000; van der Stelt et al., 2001; Cabral et al., 2008; Kozela et al., 2013; Aguado et al., 2021; Landucci et al., 2021; Lana et al., 2022 |
| Cannabidiol | CBD | CB2, GPR55, PPARγ, TRPV2, 5HTA1, direct antioxidant | Hampson et al., 1998; Jones et al., 2010; Ruiz-Valdepeñas et al., 2011; Kozela et al., 2013; Sun et al., 2017; da Silva et al., 2018; Hohmann et al., 2019; Bouskila et al., 2021; Landucci et al., 2021, 2022; Lana et al., 2022; Patel et al., 2022 | |
| Levonantradol (CP 50,556-1) | CP50,556-1 | synth | CB1/CB2 agonist | Howlett et al., 1984 |
| Decacetyllevonantradol (CP 54939) | CP54939 | CB1/CB2 agonist | Howlett et al., 1984 | |
| R(+) WIN 55212-2 | WIN 55212-2 | CB1/CB2 agonist | Nagayama et al., 1999; Baker, et al., 2000; Bilsland et al., 2006; Solbrig et al., 2010; | |
| CP55940 | CP55940 | CB1/CB2 agonist | Cabral et al., 2008 | |
| BAY 38-7271 | BAY 38-7271 | CB1/CB2 agonist | Mauler et al., 2003 | |
| SR141716 | SR141716 | CB1 antagonist | Nagayama et al., 1999; van der Stelt et al., 2001; Spyridakos et al., 2022 | |
| JWH-133 | JWH-133 | CB2 agonist | Baker, et al., 2000; Wang et al., 2018; Çakır et al., 2019 | |
| VCE-004.8 | VCE-004.8 | CB2/PPARγ agonist | Navarrete et al., 2022 | |
| AM1710 | AM1710 | CB2 agonist | Spyridakos et al., 2022 | |
| Dexabinol (HU-211) | HU-211 | NMDA receptor antagonist | Shohami et al., 1993 | |
| URB597 | URB597 | FAAH inhibitor | Celorrio et al., 2016; Wang et al., 2021 | |
| N-arachidonoyl-phenolamine (AM404) | AM404 | eCB transport inhibitor | Saliba et al., 2019 |
5-HT1A: 5-Hydroxytryptamine 1A; CB1/CB2: cannabinoid receptor 1/cannabinoid receptor 2; CBD: cannabigerol; eCB: endocannabinoid; FAAH: fatty acid amide hydrolase; GPR55: G-protein-coupled receptor 55; NMDA: N-methyl-D-aspartate; PPARγ: peroxisome proliferator antigen receptor γ; THC: Δ9-Tetrahydro-cannabinol; TRPV2: transient receptor potential V1 or vanilloid receptor.